#pharmaceuticals
Related Stories (20)
US FDA approves Takeda, Protagonist's drug for rare blood cancer - Reuters
US FDA approves Takeda, Protagonist's drug for rare blood cancer Reuters
August 28, 2026China approves J&J psoriasis pill Icotyde, says drugmaker - Reuters
China approves J&J psoriasis pill Icotyde, says drugmaker Reuters
August 27, 2026AstraZeneca-Amgen asthma drug succeeds in late-stage oesophagus disease trial - Reuters
AstraZeneca-Amgen asthma drug succeeds in late-stage oesophagus disease trial Reuters
August 27, 2026China's drug regulator accepts Novo Nordisk's application for oral Wegovy - Reuters
China's drug regulator accepts Novo Nordisk's application for oral Wegovy Reuters
August 27, 2026GSK scores regulatory wins for chronic hepatitis B drug, cancer therapy - Reuters
GSK scores regulatory wins for chronic hepatitis B drug, cancer therapy Reuters
August 24, 2026Celon Pharma's generic semaglutide drug matches Ozempic in early study, shares jump - Reuters
Celon Pharma's generic semaglutide drug matches Ozempic in early study, shares jump Reuters
August 20, 2026Moderna shares double as cancer vaccine data rekindles investor hopes - Reuters
Moderna shares double as cancer vaccine data rekindles investor hopes Reuters
August 19, 2026Novo begins study to find lowest effective dose for Wegovy pill - Reuters
Novo begins study to find lowest effective dose for Wegovy pill Reuters
August 19, 2026Lawsuit against Bristol Myers over delayed cancer drug is revived - Reuters
Lawsuit against Bristol Myers over delayed cancer drug is revived Reuters
August 13, 2026Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug - Reuters
Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug Reuters
August 12, 2026Definium says LSD-based pill reduces anxiety in late-stage study - Reuters
Definium says LSD-based pill reduces anxiety in late-stage study Reuters
August 12, 2026Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide - reuters.com
Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide reuters.com
August 12, 2026Hims & Hers' shift to branded obesity drugs drives wider quarterly loss - Reuters
Hims & Hers' shift to branded obesity drugs drives wider quarterly loss Reuters
August 10, 2026US FDA approves Replimune's skin cancer drug after prior rejections - Reuters
US FDA approves Replimune's skin cancer drug after prior rejections Reuters
August 6, 2026US FDA approves Takeda's sleep disorder pill - Reuters
US FDA approves Takeda's sleep disorder pill Reuters
August 5, 2026'No discussions' over AstraZeneca-Bristol Myers deal, senior source says - Reuters
'No discussions' over AstraZeneca-Bristol Myers deal, senior source says Reuters
August 5, 2026Eli Lilly raises annual revenue forecast as GLP-1 drugs fuel growth - Reuters
Eli Lilly raises annual revenue forecast as GLP-1 drugs fuel growth Reuters
August 5, 2026Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts - Reuters
Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts Reuters
August 4, 2026Eli Lilly to offer early access to next-gen obesity drug to some patients - Reuters
Eli Lilly to offer early access to next-gen obesity drug to some patients Reuters
August 3, 2026AstraZeneca investors balk at $400 billion Bristol Myers tie-up reports - Reuters
AstraZeneca investors balk at $400 billion Bristol Myers tie-up reports Reuters
August 3, 2026Related Pages (20)
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Ozempic-maker accuses rival of false advertising
The maker of Wegovy and Ozempic, Novo Nordisk, has launched legal action accusing its arch rival Eli Lilly of false advertising in suggesting its weight-loss drugs perform better. The Danish company
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa